Trials / Completed
CompletedNCT02358395
A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
A Phase I Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Sumitomo Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, phase 1 study of BBI608 in combination with Sorafenib. This study population is adult Japanese patients with advanced hepatocellular carcinoma in Sorafenib combination therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BBI608 | Administered continuously twice daily with doses separated by 9-15 hours. |
| DRUG | Sorafenib | Sorafenib 400 mg twice daily (800 mg total daily dose). |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
- First posted
- 2015-02-09
- Last updated
- 2022-04-12
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02358395. Inclusion in this directory is not an endorsement.